CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer

Comparison of Two-versus Three-Dimensional Treatment Planning for Patients Receiving Chest Radiotherapy for Symptom Control

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00862030

Enrollment

Registered

2009-03-16

Start date

2009-04-30

Completion date

2011-01-31

Last updated

2011-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Palliative radiotherapy, Treatment planning, Non-small cell lung cancer

Brief summary

Radiotherapy (RT) treatment to the chest is a standard way of trying to decrease symptoms like cough or shortness of breath. Before any RT can be delivered, it must be planned, either using conventional x-rays (fluoroscopy) or using computer tomography (CT) scanning. This study is being done because the investigators do not know which of these two common ways of RT planning is better for balancing both treating the cancer and decreasing side effects.

Detailed description

Standard RT planning will be performed under conventional simulation, followed by CT-simulation (for study purposes only). Retrospectively, 3D treatment fields will be designed using the CT-simulation data, and compared to the actual treatment fields planned using x-rays. Coverage of the tumour volume will be assessed, together with doses, field sizes and beam positions, to determine relative undercoverage of tumour and overcoverage of normal tissue between the two planning methods, if any.

Interventions

PROCEDURECT- simulation scan

Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with local symptoms secondary to histologically-confirmed non-small cell lung cancer * Patients who will be receiving palliative-intent external beam radiotherapy * Patients who are clinically appropriate for conventional radiotherapy planning * Patients who can provide written informed consent

Exclusion criteria

* Patients who cannot provide written informed consent

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026